Expanding Indications in Transplant Oncology

Liver transplantation is well described as the only curative treatment for cirrhosis and cirrhosis with co-morbid hepatocellular carcinoma (HCC). However, it’s utility in the management of various other primary and secondary liver cancers is gaining traction rapidly, with more thorough and broader populations continuing to qualify. This includes most prominently colorectal cancer liver metastasis (CRLM), as well as cholangiocarcinoma (CCA), neuroendocrine tumors (NET) and more. Furthermore, despite being a well-described treatment for HCC for many years, growing evidence supports a change in oncologic strategy for HCC, with broadened selection criteria and more advanced systemic and loco-regional therapies. Our review aims to describe the evidence supporting expanding indications and selection criteria for liver transplantation for various oncologic indications of primary and secondary liver tumors.